Sigrid Therapeutics, a clinical-stage health tech company utilising non-pharmaceutical technology to enhance obesity management and diabetes prevention, announced today it entered into an agreement with Cencora (formerly AmerisourceBergen) aimed at accelerating the commercialisation of its SiPore technology.
SiPore21, the company's flagship product, is currently undergoing SHINE clinical trials as an innovative medical device designed for sustained blood sugar and weight control.
Administered orally, SiPore21 utilises a carefully engineered, mesoporous silica mineral to prevent digestive enzymes from breaking down carbohydrates and fats, offering a promising alternative to pharmaceutical methods.
In addition to obesity and diabetes, Sigrid is also actively pursuing SiPore applications in other markets, including food supplements, veterinary, and oral health.
Cencora will provide a variety of services, including strategy consulting, regulatory consulting and market access support. This will aid the implementation of a market introduction strategy for SiPore technology pending regulatory approval.
“With SiPore®’s clinical development for obesity and blood sugar control advancing at a rapid pace and funding secured in our recent over-subscribed round, we are ready to accelerate commercialisation,” said Sana Alajmovic, Co-Founder & CEO of Sigrid Therapeutics. “After an extensive search, we have identified Cencora as a partner who understands fully our expectations and will be able to help us fulfil our ambition to introduce this important innovation in obesity and diabetes treatment.”
